Claims for Patent: 6,967,028

Summary for Patent: 6,967,028

Title:	Prolonged release microspheres for injectable administration
Abstract:	The present invention provides microspheres intended to be administered by injection comprising a protein active ingredient and an agent coating the active ingredient intended to prolong its release, wherein they are free of any trace of organic solvent and they can be obtained according to a coating method involving bringing the active ingredient and the coating agent into contact, with stirring, in a supercritical fluid, said coating agent being soluble in this supercritical fluid.
Inventor(s):	Dulieu; Claire (Angers, FR), Richard; Joel (Longue, FR), Benoit; Jean-Pierre (Avrille, FR)
Assignee:	Mainelab (Angers, FR) Laboratoires des Produits Ethiques Ethypharm (Houdan, FR)
Application Number:	09/873,271
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,967,028
Patent Claims:	1. Microspheres for administration by injection or by the subcutaneous or intramuscular route comprising: a protein active ingredient which has been coated by a coating agent by stirring in a supercritical fluid, wherein the coating agent is soluble in the supercritical fluid, and wherein the protein active ingredient and the coating agent in the microspheres are substantially free of any organic solvent. 2. The microspheres according to claim 1, wherein the microspheres exhibit a mean size from 0.1 to 150 .mu.m. 3. The microspheres according to claim 1, wherein the protein active ingredient is from 0.5 to 50% by weight of the microspheres. 4. The microspheres according to claim 1, wherein the protein active ingredient is selected from the group consisting of parathyroid hormone related protein (parathyroid hormone related protein), growth hormone (GH), .alpha.-, .beta.-, or .gamma.-interferons, .alpha.- or .beta.-erythropoietin (EPO), granulocyte colony stimulating factor (GCSF), granulocyte macrophage colony stimulating factor (GMCSF), PACAP polypeptide (pituitary adenylate cyclase activating polypeptide), vasoactive intestinal peptide (VIP), thyrotrophin releasing hormone (TRH), corticotrophin releasing hormone (CRH), arginine vasopressin (AVP), angiotensin, insulin, somatotropin, HBS antigen of hepatitis B virus, plasminogen tissue activator, coagulation factors VIII and IX, glucosylceramidase, sargramostim, lenograstin, filgrastin, interleukin-2, dornase-.alpha., molgramostim, PEG-L-asparaginase, PEG-adenosine deaminase, hirudin, eptacog-.alpha. (human blood coagulation factor VIla) and nerve growth factors. 5. The microspheres according to claim 4, wherein the active ingredient is .alpha.- or .beta.-erythropoietin. 6. The microspheres according to claim 1, wherein the protein active ingredient is a peptide chosen from derivatives of luteinizing hormone releasing hormone, derivatives of somatostatin, triptorelin, bombesin, calcitonin, parathyroid hormone, gastrin releasing peptide (GRP), luteinizing hormone releasing hormone (LHRH), growth hormone releasing factor (GRF), Acetyl-Ser-Asp-Lys-Pro and amylin. 7. The microspheres according to claim 1, wherein the coating agent is selected from the group consisting of: biodegradable polymers and copolymers of .alpha.-hydroxycarboxylic acids, poly (.epsilon.-caprolactone) and its derivatives, poly (.beta.-hydroxybutyrate), poly(hydroxyvalerate) and (.beta.-hydroxybutyrate-hydroxyvalerate) copolymers, polymalic acid, amphiphilic block polymers of polylactic acid-polyethylene oxide, biocompatible polymers of polyethylene glycol, polyethylene oxides, block copolymers of polyethylene oxide-polypropylene oxide, polyanhydrides, polyorthoesters, polyphosphazenes, and mixtures thereof. 8. The microspheres according to claim 1, wherein the coating agent comprises a fatty substance. 9. The microspheres according to claim 8, wherein the coating agent is a mixture of mono-, di- and triglycerides of fatty acid esters and of polyethylene glycol. 10. The microspheres according to claim 1, prepared by a process comprising: suspending the active ingredient in the supercritical fluid with stirring, dissolving the coating agent in the supercritical fluid with stirring, modifying at least one of temperature and pressure to desolvate the coating agent in a controlled manner and cause coacervation, while stirring is maintained. 11. The microspheres according to claim 10, wherein the coating agent in the supercritical fluid has a concentration of from 1.5 to 4.5 g/l. 12. The microspheres according to claim 10, wherein the coacervation temperature is from 35 to 80.degree. C., the coacervation pressure is from 100 to 250 10.sup.5 Pa, and the stirring speed is from 200 to 1000 rpm. 13. The microspheres according to claim 10, wherein the process comprises placing an insert in an autoclave and wherein the suspending of the active ingredient and dissolving of the coating agent are carried out in the insert. 14. The microspheres according to claim 3, wherein the active ingredient is from 3 to 20% by weight of the microspheres. 15. The microspheres according to claim 4, wherein the protein active ingredient is a nerve growth factor, which is selected from the group consisting of NGF, CNTF, BDNG, FGF and GDNF. 16. The microspheres according to claim 7, wherein the biodegradable polymers and copolymers of .alpha.-hydroxycarboxylic acids comprise homopolymers and copolymers of lactic and glycolic acids. 17. The microspheres according to claim 16, wherein the biodegradable polymers and copolymers of .alpha.-hydroxycarboxylic acids comprise PLA (Poly-L-lactide) and PLGA (Poly-Lactic-co-Glycolic Acid). 18. The microspheres according to claim 8, wherein the fatty substance is selected from the group consisting of tram phospholipids, triglycerides, solid fatty acid esters and mixtures thereof. 19. The microspheres according to claim 18, wherein the phospholipids are selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, diphosphatidylglycerol, dipalmitoyl-phosphatidyl-choline, dioleyl-phosphatidylethanolamine, dioleyl-phosphatidylcholine, dimyristoyl-phosphatidylglycerol, and mixtures thereof. 20. The microspheres according to claim 18, wherein the triglycerides comprise C.sub.8 to C.sub.12 triglycerides. 21. The microspheres according to claim 20, wherein the triglycerides comprise triglycerides of capric acid, caprylic acid, and mixtures thereof. 22. The microspheres according to claim 18, wherein the solid fatty acid esters comprise C.sub.8 to C.sub.18 fatty acid esters. 23. The microspheres according to claim 22, wherein the solid fatty acid esters are selected from the group consisting of ethyl palmitate, ethyl myristate, octyldodecyl myristate, and mixtures thereof. 24. The micro spheres according to claim 18, wherein the solid fatty acid esters comprise C.sub.8 to C.sub.12 fatty acid esters. 25. The microspheres according to claim 10, wherein the coating agent in the supercritical fluid has a concentration of about 2 g/l. 26. The microspheres according to claim 12, wherein the coacervation temperature is from 35 to 45.degree. C., the coacervation pressure is from 180 to 220 105 Pa, and the stirring speed is 450 rpm.

Details for Patent 6,967,028

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2020-07-31
Partner Therapeutics, Inc.	LEUKINE	sargramostim	For Injection	103362	03/05/1991		2020-07-31
Partner Therapeutics, Inc.	LEUKINE	sargramostim	Injection	103362	03/05/1991		2020-07-31
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2020-07-31